## NCTN Breast Cancer Trials Portfolio (Open as of 11/15/2025)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and study information.

## **Adjuvant Post-Neoadjuvant** Neoadjuvant Metastatic **S2212** A012103 **EAY191 CCTG MA.39** (SCARLET) HR+/HER2-(ComboMATCH) (OptimICE-PCR) **TNBC** Low risk; Node positive T2-4/N0/M0, or T1-3/N1-Early-Stage, pCR post pre-op 2/M0 chemo + pembrolizumab NRG-BR007 (DEBRA) **Sub-study: EAY191-E5** HR+/HER2-**S2206** (KRAS G12C mutation) A012303 pT1(<=2cm) pN0M0 HR+/HER2-(ShortStop-HER2) Stage II or III HER2+ Early-Stage, pCR post pre-op NRG-BR009 (OFSET) chemo + HER2 blockade HR+/HER2pT1-3/N0-1/M0, Oncotype **Recurrence Score ≤ 25, Premenopausal patients** A012301 (LoTam) HR+/HER2-Early-stage, Low molecular risk, Resected tumor ≤3cm and N0, Postmenopausal pts Legend by Subtype Status

Legend by Subtype

Green = TNBC

Orange = HER2+
(Any HR status)

Purple = HR+ and HER2-

Pink = Crossdisease trial

## NCTN Breast Cancer Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint
A012103	Ш	Inhibitor Therapy
A012301	Ш	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
		ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After
A012303	Ш	Neoadjuvant Chemotherapy with HER2 Blockade
CCTG MA.39	Ш	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
		A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative,
NRG-BR007	Ш	Oncotype Recurrence Score = 18 Breast Cancer (DEBRA)</td
		A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in
NRG-BR009	Ш	Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)</td
		Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint
S2206	Ш	Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
		Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A
S2212	Ш	Randomized Phase III Study
EAY191	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
		A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment
EAY191-E5	II	Trial